Multiple mechanisms we’re reasonably confident should do something useful.
Lots of fairly specific, granular experimental evidence from mice, strongly suggesting that FMD works and low-methionine is nearly equivalent, with a mechanism that seems like it should transfer to humans.
One RCT showing benefit in short-term biomarkers for the commercial version of FMD in humans relative to the uninterrupted baseline diet.
What we don’t have is:
Fine-grained experimental evidence in humans directly comparing the commercialized FMD to other sorts of “clean eating.”
Direct experimental evidence in humans that a low-methionine regime will approximate the commercialized FMD.
It seems like the state of the evidence here is:
Multiple mechanisms we’re reasonably confident should do something useful.
Lots of fairly specific, granular experimental evidence from mice, strongly suggesting that FMD works and low-methionine is nearly equivalent, with a mechanism that seems like it should transfer to humans.
One RCT showing benefit in short-term biomarkers for the commercial version of FMD in humans relative to the uninterrupted baseline diet.
What we don’t have is:
Fine-grained experimental evidence in humans directly comparing the commercialized FMD to other sorts of “clean eating.”
Direct experimental evidence in humans that a low-methionine regime will approximate the commercialized FMD.
Does that seem right?